Genentech, a member of the Roche Group received approval from the U.S. FDA for Alecensa (alectinib) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alecensa is the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor.        The approval is based on positive results from the Phase II...